News

Arvinas, Pfizer Seek FDA Approval of Vepdegestrant in Breast Cancer
Arvinas and Pfizer have filed for U.S. Food and Drug Administration approval of their proposed breast-cancer drug vepdegestrant in certain patients with estrogen-receptor mutations.
BioPharma Dive3d
Full Arvinas, Pfizer data confirm potential, limits of ‘Protac’ drug in breast cancer
While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...
PharmExec1d
Pfizer, Arvinas’ Novel PROTAC ER Degrader Shows Significant Survival Benefit in ER+/HER2- Advanced Breast Cancer
Results from the Phase III VERITAC-2 trial demonstrated that vepdegestrant reduced the risk of disease progression or death ...
Pfizer-Arvinas breast cancer drug tops AstraZeneca's in delaying progression
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...
TipRanks on MSN4d
Arvinas-Pfizer partnership dynamics may shift, says H.C. Wainwright
H.C. Wainwright analyst Andrew Fein notes that Arvinas (ARVN) shared the final data from the VERITAC-2 trial, which the firm sees positioning ...
Pfizer/Arvinas to seek FDA nod for jointly developed cancer therapy in H2
Pfizer (NYSE:PFE) and Arvinas (NASDAQ:ARVN) announced Saturday their plans to submit a new drug application with the Food and ...
TMCnet6d
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer
Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared to fulvestrant in second line-plus patients with ...
The Pharma Letter4d
ASCO: Positive Phase III results for Arvinas and Pfizer's vepdegestrant
Arvinas (Nasdaq: ARVN) and Pfizer (NYSE: PFE) today announced detailed results from the Phase III VERITAC-2 clinical trial ...
Nasdaq6d
Arvinas and Pfizer Announce Phase 3 VERITAC-2 Trial Results Showing Vepdegestrant Improves Progression-Free Survival in ESR1-Mutant Breast Cancer Patients
and NEW YORK, May 31, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced detailed results from the Phase 3 VERITAC-2 clinical trial (NCT05654623 ...
Devdiscourse6d
Breakthrough Breast Cancer Treatment by Pfizer and Arvinas Outshines Rival
Clinical trial results reveal an experimental treatment by Pfizer and Arvinas that delays breast cancer progression by over ...
Yahoo Finance6d
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer
NEW HAVEN, Conn. and NEW YORK, May 31, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced detailed results from the Phase 3 VERITAC-2 clinical trial ...